Associated Papers
Patients with Papillary Renal Cancer and Germline Duplication of MET Exons 5-21.
Mikhaylenko DS et al.
Biomedicines, 2025
PAX5 Alterations in a Consecutive Childhood B-Cell Acute Lymphoblastic Leukemia Cohort Treated Using the ALL IC-BFM 2009 Protocol.
Črepinšek K et al.
Cancers, 2024
38539499 (PubMed )
Supplement: cancers-16-01164-s001.zip › cancers-2903666-supplementary.xlsx › Suppl._Table_S3
Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.
Wong D et al.
Cancer Discovery, 2024
37874259 (PubMed )
Supplement: cd-23-0456_table_s2_suppst2.xlsx › Sheet1
Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Rolfes M et al.
Cancers, 2022
35805063 (PubMed )
Supplement: cancers-14-03292-s001.zip › cancers-1740746-supplementary.pdf
Characterisation of protein-truncating and missense variants in PALB2 in 15 768 women from Malaysia and Singapore.
Ng PS et al.
Journal of Medical Genetics, 2022
Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification.
Ho PJ et al.
Bmc Medicine, 2022
35468796 (PubMed )
Supplement: 12916_2022_2334_MOESM2_ESM.xlsx › sT2
Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience.
Youssef ASE et al.
Current Issues in Molecular Biology, 2022
35723313 (PubMed )
Supplement: cimb-44-00090-s001.zip › Table_S3.xlsx › Var._associated_with_CRC_only
Germline breast cancer susceptibility genes, tumor characteristics, and survival.
Ho PJ et al.
Genome Medicine, 2021
34857041 (PubMed )
Supplement: 13073_2021_978_MOESM1_ESM.xlsx › sT2
Profile of esophageal squamous cell carcinoma mutations in Brazilian patients.
Munari FF et al.
Scientific Reports, 2021
34663841 (PubMed )
Supplement: 41598_2021_208_MOESM1_ESM.xlsx › Supp.T1
Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan.
Wu KS et al.
Cancers, 2020
32168907 (PubMed )
Supplement: cancers-12-00653-s001.zip › cancers-720756-suppl-XML › cancers-720756-Table_S2.xlsx › ___1
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Castroviejo-Bermejo M et al.
Embo Molecular Medicine, 2018
Select a paper to view details